Spyre Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Spyre Therapeutics Inc.
- Former names
- Aeglea BioTherapeutics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SYRE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001636282
- EIN
- 46-4312787
Board of directors
-
Alison Frances Lawton · DirectorSince 2023
-
Cameron Turtle · Director · Chief Executive OfficerSince 2023
-
Hunter C. Smith · DirectorSince 2023
-
Ivana Magovcevic-Liebisch · DirectorSince 2023
-
Jeffrey W. Albers · DirectorSince 2023
-
Laurie Stelzer · DirectorSince 2023
- Since 2024
-
Michael Thomas Henderson · DirectorSince 2023
- Since 2023
-
Russell J. Cox · DirectorSince 2023
-
Sandra Milligan · DirectorSince 2024
- Since 2023
Chief executives
Cameron Turtle
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 29, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.7%
Board connections
10 of this board's directors also sit on 22 other boards.
- via Alison Frances Lawton, Peter Evan Harwin and Tomas Kiselak
- via Cameron Turtle, Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Cameron Turtle and Peter Evan Harwin
- via Russell J. Cox and Sandra Milligan
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Ivana Magovcevic-Liebisch
- via Mark C. McKenna
- via Peter Evan Harwin
- via Mark C. McKenna
- via Mark C. McKenna
- via Jeffrey W. Albers
- via Laurie Stelzer
- via Mark C. McKenna
- via Laurie Stelzer
- via Alison Frances Lawton
- via Ivana Magovcevic-Liebisch
- via Laurie Stelzer
- via Alison Frances Lawton
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $436,706,843
- 79 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Open-market sale | −18,232 | $89.35 | $1,629,029 |
| Sep 2, 2026 | King-Jones Heidy Officer (See Remarks) | Option exercise | +400 | $14.50 | $5,800 |
| Sep 2, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −400 | $90.00 | $36,000 |
| Sep 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Option exercise | +7,500 | $14.50 | $108,750 |
| Sep 1, 2026 | King-Jones Heidy Officer (See Remarks) | Option exercise | +27,999 | $14.50 | $405,986 |
| Sep 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −2,500 | $86.36 | $215,900 |
| Sep 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Open-market sale | −900 | $86.25 | $77,625 |
| Sep 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −4,845 | $86.40 | $418,608 |
| Sep 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −8,400 | $87.15 | $732,060 |
| Sep 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Open-market sale | −4,384 | $87.11 | $381,890 |
| Sep 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −16,548 | $87.20 | $1,442,986 |
| Sep 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −3,700 | $88.06 | $325,822 |
| Sep 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Open-market sale | −2,016 | $88.03 | $177,468 |
| Sep 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −6,206 | $88.17 | $547,183 |
| Sep 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −400 | $89.07 | $35,628 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.